| 1.8 0.05 (2.86%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.83 | 1-year : | 3.42 |
| Resists | First : | 2.42 | Second : | 2.93 |
| Pivot price | 2.26  |
|||
| Supports | First : | 1.61 | Second : | 1.34 |
| MAs | MA(5) : | 1.88 |
MA(20) : | 2.37 |
| MA(100) : | 2.62 |
MA(250) : | 3.15 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.3  |
D(3) : | 7.3 |
| RSI | RSI(14): 28 |
|||
| 52-week | High : | 6.07 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDXS ] has closed above bottom band by 13.2%. Bollinger Bands are 130.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.72 - 1.73 | 1.73 - 1.74 |
| Close: | 1.78 - 1.8 | 1.8 - 1.82 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Mon, 10 Nov 2025
Codexis, Inc. Leases New GMP Manufacturing Facility in Hayward, California to Expand siRNA Production Capabilities - Quiver Quantitative
Mon, 10 Nov 2025
Codexis (NASDAQ: CDXS) signs lease to add siRNA GMP capacity; work begins early 2026 - Stock Titan
Sat, 08 Nov 2025
Codexis, Inc. (NASDAQ:CDXS) Q3 2025 Earnings Call Transcript - Insider Monkey
Sat, 08 Nov 2025
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates - sharewise.com
Fri, 07 Nov 2025
Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ... - Yahoo Finance
Thu, 06 Nov 2025
Codexis: Q3 Earnings Snapshot - San Francisco Chronicle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 79.5 (%) |
| Shares Short | 4,750 (K) |
| Shares Short P.Month | 5,630 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -113.7 % |
| Operating Margin | -84 % |
| Return on Assets (ttm) | -26.5 % |
| Return on Equity (ttm) | -111 % |
| Qtrly Rev. Growth | 92 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -2.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.9 |
| Price to Sales | 2.84 |
| Price to Cash Flow | -2.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|